N-Ethylhexedrone
N-Ethylhexedrone is a stimulant of the cathinone class that acts as a norepinephrine–dopamine reuptake inhibitor with IC50 values of 0.0978 and 0.0467 μM, respectively. N-Ethylhexedrone was first mentioned in a series of patents by Boehringer Ingelheim in the 1960s which led to the development of the better-known drug methylenedioxypyrovalerone. Since the mid-2010s, N-ethylhexedrone has been sold online as a designer drug. In 2018, N-ethylhexedrone was the second most common drug of the cathinone class to be identified in Drug Enforcement Administration seizures.Legal status
In the United States, N-ethylhexedrone is a Schedule I Controlled Substance. N-Ethylhexedrone is illegal in Japan, and is listed as a potentially harmful substance, but not banned in Sweden. In December of 2019, the UNODC announced scheduling recommendations placing N-ethylhexedrone into Schedule II.
